World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 2 November 2020
Main ID:  ISRCTN68411960
Date of registration: 01/10/2014
Prospective Registration: No
Primary sponsor: University of Basel
Public title: Impact of disease burden and setting-specific interventions on schoolchildren?s cardio-respiratory physical fitness and psychosocial health in Port Elizabeth, South Africa
Scientific title: Impact of disease burden and setting-specific interventions on schoolchildren?s cardio-respiratory physical fitness and psychosocial health in Port Elizabeth, South Africa: a cross-sectional epidemiological survey and cluster randomized controlled trial
Date of first enrolment: 01/09/2014
Target sample size: 1000
Recruitment status: Completed
URL:  http://isrctn.com/ISRCTN68411960
Study type:  Interventional
Study design: 
1. Cross-sectional clinical epidemiological survey
2. Cluster randomized controlled trial (Quality of life)
 
Phase:  Not Applicable
Countries of recruitment
South Africa
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name: Uwe    PĆ¼hse
Address:  University of Basel Department of Sport, Exercise and Health Birsstrasse 320 B CH-4052 Basel 4052 Basel Switzerland
Telephone: +41 (0)61 377 8780/84
Email: uwe.puehse@unibas.ch
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Willing to participate in the study
2. Be in possession of a written informed consent by a parent/guardian on behalf of the child
3. Not participating in other studies
4. Being a primary school child aged 9-12 years, male or female
5. Absence of ill-health condition (e.g. severe anaemia, respiratory disease or other major illnesses), as assessed by a medical doctor at baseline.

Exclusion criteria:
1. Children below the age of 9 years or above 12 years
2. Not having a written informed consent or no parental/legal guardian?s permission to participate
3. Suffer from medical conditions which prevent participation in the study, as determined by qualified medical personnel
4. Attending other clinical trials during the study period.


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Communicable diseases (e.g. intestinal protozoa and helminth infections) and non-communicable chronic conditions (e.g. type 2 diabetes and malnutrition)
Infections and Infestations
Intervention(s)
The following intervention toolbox is proposed but the specific combination of interventions to be used will be governed by the key findings from the initial cross-sectional baseline survey: Physical fitness programmes, health education and administration of nutritional supplements or treatments. All participants of the study will be treated against soil-transmitted helminthiasis and schistosomiasis with a single dose of albendazole (400 mg) and praziquantel (40 mg/kg), respectively, at baseline, 1 year and 2 years (follow-up assessment) after launch of the study.
Primary Outcome(s)

1. The prevalence of communicable diseases (e.g. intestinal protozoa and helminth infections) and non-communicable chronic conditions (e.g. type 2 diabetes and malnutrition).
2. Differences (non-infected vs. infected) and changes (before and after treatment) in physical fitness levels, psychosocial health and cognitive performance.
Secondary Outcome(s)

1. Reduction of infection prevalence and intensity of soil-transmitted helminths and schistosomiasis.
2. Differences and changes in disease-related morbidity measures (malnutrition and anaemia).

Treatment will be administered to all study participants directly after baseline assessments, 1 year and 2 years after baseline. Reassessment of parasitic infection, anthropometric and haemoglobin measurements, clinical examination, physical fitness and cognitive performance will take place at the end of the study follow-up, 2 years after baseline.
Secondary ID(s)
N/A
Source(s) of Monetary Support
Swiss National Science Foundation (SNSF) (reference no. IZLSZ3_149015) (Switzerland)
Secondary Sponsor(s)
Swiss Tropical and Public Health Institute (Switzerland)
Nelson Mandela Metropolitan University (South Africa)
Ethics review
Status:
Approval date:
Contact:
1. Research Ethics Committee (Human) from the Nelson Mandela Metropolitan University (NMMU), Port Elizabeth, South Africa, 04/07/2014, ref. H14-HEA-HMS-002 2. Ethics Committee northwest/central Switzerland, 01/08/2014, ref. 2014-179
Results
Results available: Yes
Date Posted:
Date Completed: 31/08/2017
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history